Surrogate markers to assess new therapies for drug-resistant tuberculosis

References

• Wright A, Bai G, Barrera L et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. Morb. Mortal. Wkly Rep.55(11), 301–305 (2006).
   PubMedGoogle Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med.170(10), 1131–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis.41(2), 201–208 (2005).
   PubMed Web of Science ®Google Scholar
• Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med.125(7), 605–613 (1996).
   PubMed Web of Science ®Google Scholar
• CAST II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med.327(4), 227–233 (1992).
   PubMed Web of Science ®Google Scholar
• Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Soc. Appl. Bacteriol. Symp. Ser.25, S72–S80 (1996).
   Google Scholar
• Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am. Rev. Respir. Dis.147(4), 1062–1063 (1993).
   PubMed Web of Science ®Google Scholar
• Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest117(3), 744–751 (2000).
   PubMed Web of Science ®Google Scholar
• Priftin (rifapentine) package insert. In: Physician’s Desk Reference. Medical Economics, NJ, USA 1334–1338 (1999).
   Google Scholar
• Benator D, Bhattacharya M, Bozeman L et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet360(9332), 528–534 (2002).
   PubMed Web of Science ®Google Scholar
• Brindle R, Odhiambo J, Mitchison DA. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm. Med.1(1), 2 (2001).
   PubMedGoogle Scholar
• Jindani AJ, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis.121, 939–949 (1980).
   PubMed Web of Science ®Google Scholar
• Davies GR, Brindle R, Khoo SH, Aarons LJ. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob. Agents Chemother.50(9), 3154–3156 (2006).
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet349(9064), 1513–1515 (1997).
   PubMed Web of Science ®Google Scholar
• Giosue S, Casarini M, Ameglio F et al. Aerosolized interferon-α treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw.11(1), 99–104 (2000).
   PubMed Web of Science ®Google Scholar
• Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N et al. Adjuvant interferon γ in patients with drug - resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis.4(1), 44 (2004).
   PubMed Web of Science ®Google Scholar
• Koh WJ, Kwon OJ, Suh GY et al. Six-month therapy with aerosolized interferon-γ for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci.19(2), 167–171 (2004).
   PubMed Web of Science ®Google Scholar
• Dawson R, Condos R, Lucke W et al. Randomized clinical trial of aerosol or subcutaneous interferon γ plus DOTS versus DOTS alone for cavitary tuberculosis: early results. Am. J. Respir. Crit. Care Med.S2, A745 (2006).
   Google Scholar
• Intermune Investor Relations Press Release. InterMune Enrolls First Patient in Phase III Trial in Multidrug-Resistant Tuberculosis. 8–1-2000.
   Google Scholar
• Raju B, Hoshino Y, Kuwabara K et al. Aerosolized γ interferon (IFN-γ) induces expression of the genes encoding the IFN-γ-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect. Immun.72(3), 1275–1283 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson BJ, Bekker LG, Rickman R et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber. Lung Dis.78(3–4), 195–203 (1997).
   PubMedGoogle Scholar
• Johnson JL, Ssekasanvu E, Okwera A et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.168, 185–191 (2003).
   PubMed Web of Science ®Google Scholar
• Ribeiro-Rodrigues R, Resende CT, Johnson JL et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin. Diagn. Lab. Immunol.9(4), 818–823 (2002).
   PubMedGoogle Scholar
• Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN-γ in tuberculous pleuritis. J. Immunol.145, 149–154 (1990).
   PubMed Web of Science ®Google Scholar
• Bekker LG, Maartens G, Steyn L, Kaplan G. Selective increase in plasma tumor necrosis factor-α and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J. Infect. Dis.178(2), 580–584 (1998).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Perkins M, Phillips M et al. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J. Infect. Dis.178, 1115–1121 (1998).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Phillips M, Johnson JL et al. Inhibition of INH-induced expression of M. tuberculosis antigen 85 in sputum: a potential surrogate marker in TB chemotherapy trials. Antimicrob. Agents Chemother.45(4), 1302–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Aung H, Toossi Z, Wisnieski JJ et al. Induction of monocyte expression of TNFα by the 30-kD α antigen of M. tuberculosis, and synergism with fibronectin. J. Clin. Invest.98(5), 1261–1268 (1996).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS18(2), 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Mayanja-Kizza H, Jones-Lopez EC, Okwera A et al. Immunoadjuvant therapy for HIV-associated tuberculosis with prednisolone: a Phase II clinical trial in Uganda. J. Infect. Dis.191(6), 856–865 (2005).
   PubMed Web of Science ®Google Scholar
• Karakousis PC, Yoshimatsu T, Lamichhane G et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J. Exp. Med.200(5), 647–657 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Vinhas SA, Johnson JL et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J. Infect. Dis.187, 270–278 (2003).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Song HY, Whalen C, Okwera A. TB chemotherapy: antagonism between immunity and sterilization. Am. J. Respir. Crit. Care Med.169(6), 771–772 (2004).
   PubMedGoogle Scholar
• Heifets LB, Good RC. Current laboratory methods for the diagnosis of tuberculosis. In: Tuberculosis: Pathogenesis, Protection, and Control. Bloom BR (Ed.). ASM Press, DC, USA, 94 (1994).
   Google Scholar
• Wallis RS, Patil S, Cheon SH et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother.43(11), 2600–2606 (1999).
   PubMed Web of Science ®Google Scholar
• Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest113(2), 379–386 (1998).
   PubMedGoogle Scholar
• Wallis RS, Perkins M, Phillips M et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.161, 1076–1080 (2000).
   PubMedGoogle Scholar
• Hasegawa N, Miura T, Ishizaka A, Yamaguchi K, Ishii K. Detection of mycobacteria in patients with pulmonary tuberculosis undergoing chemotherapy using MGIT and egg-based solid medium culture systems. Int. J. Tuberc. Lung Dis.6(5), 447–453 (2002).
   PubMedGoogle Scholar